# Bristol-Myers Squibb Company (BMY) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $66.82, market value $136.5 billion.

## Valuation
- **P/E (trailing): 14.7×** (5-yr avg 16.0×, 3-yr avg 13.4×). Bristol-Myers Squibb Company trades at 14.7× trailing earnings, close to its own five-year average of 16.0×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 10.2×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.06**. A PEG of 0.06 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.8×**. Each dollar of revenue is priced at 2.8×.
- **Price / book: 6.1×**. The shares trade at 6.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 8.4%** (5-yr avg 12.2%). Free cash flow equals 8.4% of the market value, below its five-year average of 12.2%, so the shares are pricier on cash than usual. Above 5% is generally attractive.
- **Earnings yield: 6.8%**. The inverse of the P/E: 6.8% of the price is earned each year.

## Profitability
- **Net margin: 14.6%**. 14.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 38.2%**. 38.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on assets: 10.3%**. Each dollar of assets produces 10.3% of profit.

## Growth
- **Revenue growth (1 yr): -0.2%** (3-yr 1.4%/yr, 5-yr 2.5%/yr). Revenue fell 0.2% over the last year, against 2.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 178.5%** (3-yr 5.5%/yr). Earnings per share rose 178.5%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 2.4%/yr**. Free cash flow has compounded at 2.4% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 2.44**. Debt is 2.44 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 3.77%** ($2.51 per share, trailing). Bristol-Myers Squibb Company yields 3.77%, an income-level yield.
- **Payout ratio: 72%** (45% of free cash flow). 72% of earnings goes out as dividends, leaving a thin cushion.
- **Consecutive years of increases: 4**. 4 straight years of increases.
- **Dividend growth (5 yr): 1.6%/yr** (1-yr 3.3%). The dividend has grown 1.6% a year over five years.

## Analyst view
- **Analyst consensus: buy** (24 analysts). 24 analysts cover Bristol-Myers Squibb Company; the consensus is buy, with an average price target of $66.21 (-1% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 50.0%** (YTD 28.1%, 3-mo 18.0%). The shares are up 50.0% over twelve months including dividends.
- **From 52-week high: -2.7%** (57.1% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 0.25** (volatility 27%). Beta of 0.25 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BMY · Page: https://foliofundamentals.com/stocks/bmy

Not investment advice.